Compare AstraZeneca plc (AZN) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs VF Corp — how do they compare? AstraZeneca plc trades at $157.85 (market cap $248.14B), while VF Corp trades at $14.59 (market cap $5.81B). The key difference: AstraZeneca plc is far larger — about 42.7× VF Corp's market cap, and VF Corp pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| AZN | VFC | |
|---|---|---|
Market Cap | $248.14B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $21.55 |
52-Week Low | $147.06 | $12.21 |
Enterprise Value | $275.41B | $10.09B |
Dividend Yield | 2.01% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
VFC trades at $14.90, down 0.6% on the day, near the low end of analyst targets. Technical indicators are bearish, with mixed recent earnings showing a Q4 beat but Q1 and Q2 misses. Revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company faces brand-specific headwinds, particularly with Vans, while maintaining a reasonable P/S ratio of 0.62.
The outlook is cautious. Deleveraging progress and a raised 2027 revenue outlook offer some optimism, but persistent Vans weakness and macro pressures pose significant risks. Analyst consensus is Hold, with a $17.44 price target suggesting limited upside from current levels amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
